In 2005, the British Journal of Pharmacology published a study evaluating the ability of cannabidiol (CBD) to impair the migration of tumor cells and thus act as a potential antitumoral compound. The results of the study reinforce the evidence of antitumoral properties of CBD, demonstrating its ability to limit tumor invasion, although the mechanism of its pharmacological effects remains to be clarified. This antimigratory property, together with the known antiproliferative and apoptotic features of CBD, strengthen the evidence for its use as a potential antitumoral agent. (more…)
In a 2003 issue of the Journal of International Neuropsychological Society is this study looking at the possible long-term residual effects of using cannabis. The results of this meta-analytic study failed to reveal a substantial, systematic effect of long-term, regular cannabis consumption on the neurocognitive functioning of users who were not acutely intoxicated. (more…)
Published in 2012, this study concluded that elevation of cannabinoid receptor activity either by pharmacological blockade of the degradation of cannabinoids or by receptor agonists could be a promising strategy for slowing down the progression of brain aging and for alleviating the symptoms of neurodegenerative disorders.
Published in the British Journal of Cancer in 2006, these scientists reported ‘the first clinical study aimed at assessing cannabinoid antitumoral action, specifically a pilot phase I trial in which nine patients with recurrent glioblastoma multiforme were administered THC intratumoraly. The patients had previously failed standard therapy (surgery and radiotherapy) and had clear evidence of tumour progression’. (more…)
Results from a 2005 study out of Spain, published in the Journal of Neuroscience, indicate that cannabinoid receptors are important in the pathology of Alzheimer’s Disease and that cannabinoids succeed in preventing the neurodegenerative process occurring in the disease. (more…)